Zacks Investment Research Downgrades Osmotica Pharmaceuticals (NASDAQ:OSMT) to Sell

Zacks Investment Research lowered shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) from a hold rating to a sell rating in a report issued on Friday morning, Zacks.com reports.

According to Zacks, “Osmotica Pharmaceuticals Public Limited Company operates as a biopharmaceutical company. It offers tablets, dietary supplements and drugs for the treatment of women’s health. The company’s product pipeline consists of Methylphenidate HCl ER 72 mg Tablets, Osmolex ER(TM), Lorzone(R), ConZip(R), Divigel(R) and OB Complete(R). Its delivery system includes Osmodex(R) drug delivery system. Osmotica Pharmaceuticals Public Limited Company is based in Bridgewater, New Jersey. “

Several other equities research analysts have also recently commented on the company. Barclays started coverage on Osmotica Pharmaceuticals in a report on Tuesday, June 11th. They issued an overweight rating and a $11.00 price target for the company. Wells Fargo & Co set a $14.00 price target on Osmotica Pharmaceuticals and gave the company a buy rating in a report on Thursday, March 28th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Osmotica Pharmaceuticals has a consensus rating of Buy and a consensus price target of $14.00.

NASDAQ:OSMT opened at $3.29 on Friday. Osmotica Pharmaceuticals has a one year low of $2.20 and a one year high of $9.90. The company has a quick ratio of 1.41, a current ratio of 1.70 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $169.50 million and a P/E ratio of -6.45.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.08). The company had revenue of $57.13 million during the quarter, compared to analysts’ expectations of $53.58 million. As a group, equities research analysts anticipate that Osmotica Pharmaceuticals will post -0.25 earnings per share for the current year.

Institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new position in shares of Osmotica Pharmaceuticals during the first quarter worth approximately $45,000. Deutsche Bank AG bought a new position in shares of Osmotica Pharmaceuticals in the fourth quarter valued at $111,000. Sofinnova Investments Inc. bought a new position in shares of Osmotica Pharmaceuticals in the fourth quarter valued at $1,961,000. Millennium Management LLC bought a new position in shares of Osmotica Pharmaceuticals in the fourth quarter valued at $2,568,000. Finally, Great Point Partners LLC bought a new position in shares of Osmotica Pharmaceuticals in the fourth quarter valued at $11,625,000. Institutional investors own 11.64% of the company’s stock.

Osmotica Pharmaceuticals Company Profile

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

Further Reading: Book Value Per Share – BVPS

Get a free copy of the Zacks research report on Osmotica Pharmaceuticals (OSMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.